Arvinas
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
CEOJohn G. Houston
CEOJohn G. Houston
Employees445
Employees445
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2013
Founded2013
Employees445
Employees445
ARVN Key Statistics
Market cap1.27B
Market cap1.27B
Price-Earnings ratio-3.97
Price-Earnings ratio-3.97
Dividend yield—
Dividend yield—
Average volume758.40K
Average volume758.40K
High today$18.84
High today$18.84
Low today$17.52
Low today$17.52
Open price$18.26
Open price$18.26
Volume504.86K
Volume504.86K
52 Week high$53.08
52 Week high$53.08
52 Week low$17.08
52 Week low$17.08
ARVN News
Simply Wall St 19h
Arvinas Repeat Insider Selling Not A Positive IndicatorQuite a few Arvinas, Inc. ( ) insiders sold their shares over the past year, which may be a cause for concern. When evaluating insider transactions, knowing whe...
Analyst ratings
91%
of 22 ratingsBuy
90.9%
Hold
9.1%
Sell
0%